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A significant increase in the activity of serum alkaline phosphatase is commonly reported 
in patients on long-term antiepileptic treatment or after any uncomplicated fracture.  We 
report a case of a 34-year old gentleman on five different anticonvulsant medications for 
treatment of the rare autosomal recessive neurodegenerative disorder, Unverricht-
Lundborg disease.  He presented with bilateral metatarsal fractures: however, his serum 
alkaline phosphatase activity remained below the lower limit of reference range.  
Biochemical laboratory investigations revealed a long standing low serum alkaline 
phosphatase and raised plasma pyridoxal-5’-phosphate level.  Sequencing of genomic 
DNA revealed that he is heterozygous for a mutation in the ALPL gene which is 
consistent with the diagnosis of hypophosphatasia. 
Keywords
Hypophosphatasia, Unverricht-Lundborg disease, Alkaline phosphatase enzyme
Introduction
Hypophosphatasia (HPP) is a rare inherited genetic condition, with heterogeneous 
phenotype and variable severity, occurring secondary to inactivating mutations of the 
tissue non-specific isoenzyme of alkaline phosphatase (TNSALP).1 Six forms of the 
disease have been described according to the age at presentation and clinical severity.  
The earlier the onset, the more severe the condition with the mildest form occurring in 
adulthood, when patients usually suffer from premature teeth loss with little or no other 
skeletal disease.2 The biochemical hallmarks of the disease are; reduced serum alkaline 
phosphatase (ALP) activity, with an increase in plasma pyridoxal-5’-phosphate (PLP). 
Molecular analysis of TNSALP gene is sometimes necessary to distinguish HPP from 
other metabolic skeletal diseases.3 With the availability of an enzyme replacement 
therapy for treatment of HPP, it is important that laboratories report reliable age and sex-
related ALP reference ranges to aid in diagnosis of this very rare genetic metabolic 
disease.4 
We report here the first case, to our knowledge, of Unverricht-Lundborg disease 
with a recent diagnosis of adult hypophosphatasia.  
Case presentation
The duty biochemist noted a low serum alkaline phosphatase in a 35-year-old 
male patient who presented with bilateral metatarsal fractures. The man was known to 
have Unverricht-Lundborg syndrome, an autosomal recessive progressive myoclonic 
epilepsy secondary to biallelic mutation of the cystatin B (CSTB) gene.  He was on five 
different anti-epileptic treatment including; sodium valproate, piracetam, levetiracetam, 
clonazepam and zonisamide.  
He first presented at the age of 10 with generalised tonic-clonic seizures. EEG 
showed photosensitivity and he was diagnosed with idiopathic generalised epilepsy with 
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photosensitivity.  He was started on sodium valproate. At the age of 13, he started to 
develop myoclonic jerks particularly at night. His MRI brain was normal. His condition 
deteriorated with time: myoclonic jerks became very frequent and disabling with decline 
in cognitive function, though retaining full capacity, necessitating the use a 
wheelchair by the age of 23.  Sequencing of the CSTB gene, encoding cystatin B, 
revealed that he was compound heterozygous for a dodecamer expansion mutation and a 
point mutation, consistent with a diagnosis of progressive myoclonic epilepsy type 1-
Unverricht-Lundborg disease.5 
Serum analysis showed low ALP with raised serum phosphate despite normal 
renal function (Table1). He had previous past history of metatarsal fractures and possible 
right fifth rib fracture.  His medical records revealed low serum ALP (figure 1) and raised 
serum phosphate on many separate occasions over the past 16 years.  Other biochemistry 
was normal including thyroid, renal and liver functions except for an isolated rise in 
serum alanine transaminase secondary to fatty liver. He was on colecalciferol 400 
units/calcium carbonate 1.5g chewable tablets once daily with adequate vitamin D 
status.  During his last hospital admission, CT showed fractures involving the 
second, third and fourth metatarsal bases and middle cuneiform on the left foot and 
the second and fourth metatarsal bones of the right foot.  Despite his uncomplicated 
fractures and long term treatment with sodium valproate6, both are known to cause an 
increase in serum alkaline phosphatase, his serum ALP remained low. No other cause of 
low serum ALP such as metabolic bone disease, coeliac disease or malnutrition was 
identified in this patient.  
TNSALP catalyses the hydrolysis of pyrophosphate to inorganic phosphate, the 
latter crystallises with calcium, forming the hydroxyapatite required for adequate bone 
and teeth mineralisation. Reduced TNSALP activity results in accumulation of 
pyrophosphate and an increase in articular calcification, causing joint stiffness and pain.  
Pyridoxal 5’-phosphate (PLP), an activated form of vitamin B6, is another TNSALP 
substrate which is required as a cofactor in neuronal cells to form neurotransmitters.  PLP 
is dephosphorylated by TNSALP to pyridoxal which then crosses the blood-brain barrier 
to be re-generated as PLP. Phosphoethanolamine (PEA), though not a confirmed 
TNSALP substrate, is raised in serum and urine of TNSALP knockout mice but it is not 
pathognomic for the condition and its clinical significance is unknown.7  
In view of the history of recurrent fractures and the long standing low serum ALP, 
we investigated the possibility of hypophosphatasia.  Plasma PLP level was raised (233 
nmol/L –reference range 40-100): he was not taking vitamin B6 supplementation. 
Urinary PEA was normal. Sequencing of the ALPL gene was performed using the Ion 
S5 Next Generation sequencing platform (Thermofisher) and the BigDye® 
terminator purification kit. The patient was found to be heterozygous for a 
p.(Ala443Val) c.1328C>T, likely pathogenic mutation8 in exon 12 of the ALPL gene, 
which is consistent with a diagnosis of hypophosphatasia. 
Discussion
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Serum ALP activity is usually measured to detect an increase in its activity.  The 
clinical significance of the rare finding of low serum ALP activity in the adult population 
is not universally recognised. Among various causes of low serum ALP is 
hypophosphatasia (HPP), a rare genetic disorder with a wide spectrum clinical severity 
and variable expressivity.9 Six clinical phenotypes have been described based on the age 
of presentation and the severity of symptoms; perinatal lethal, perinatal benign, infantile, 
childhood, adult and odontohypophosphatasia. The severe HPP forms (perinatal and most 
infantile cases) are transmitted in an autosomal recessive manner. The milder forms such 
as adult and odontohypophosphatasia, may be inherited as dominant or recessive traits.1 
ALP is a membrane-bound enzyme that can be classified into three tissue specific 
isoenzymes that are intestinal, placental, germ cell and one tissue non-specific ALP 
(TNSALP) expressed in liver, bone and kidney.  Loss-of-function mutations in the gene 
encoding the TNSALP isoenzyme lead to defective mineralisation of the skeleton and 
teeth. The enzyme is also responsible for dephosphorylation of PLP to pyridoxine so that 
it can cross the blood brain barrier where it is required for synthesis of gamma-
aminobutyric acid (GABA).7 Some TNSALP mutations are associated with reduced 
activity to dephosphorylate PLP leading to reduced GABA synthesis and seizures.10 
Increased urinary PEA levels are noted in some patients, but this is not sensitive 
diagnostic marker for the disease as some patients with HPP have normal PEA excretion.  
Adult hypophosphatasia, typically presenting in middle age, is characterised by 
foot pain secondary to stress fractures in the metatarsals and is sometimes associated with 
premature loss of deciduous teeth. Heterozygote carriers usually exhibit some residual 
TNSALP activity and present with a milder form of the disease.  The mutation found in 
our patient has been previously reported as a dominant negative mutation, and probably 
accounts for the mild HPP phenotype observed in this case.11 Our patient had no 
history of premature loss of deciduous teeth.  Bone densitometry was planned but 
did not take place on this admission as the patient moved out of the area. 
  Bone remodeling is a dynamic process requiring a balance between bone 
resorption or osteoclast activity and bone formation or osteoblast activity.  Our 
patient had two genetically inherited conditions that have implications on bone 
metabolism.  He is a compound heterozygote for the rare genetic condition, Unverricht-
Lundborg disease.  This condition occurs due to mutations in CSTB producing 
dysfunctional cystatin B, which is a known inhibitor of the lysosomal cathepsins.  It has 
been shown that decreased expression of CSTB mRNA enhances cathepsin activity.12 
CSTB inhibits cathepsin K activity which is essential for osteoclast function and bone 
resorption. Patients with Unverricht-Lundborg disease may manifest with bone changes, 
such as thickening of the skull and long bones, caused by reduced CSTB activity leading 
to loss of cathepsin K inhibition and accelerated bone resorption cycle.13 The exact 
mechanism, by which lack of CSTB leads to the observed skeletal changes, is not fully 
elucidated.  Interestingly, our patient had no evidence of similar bone changes in any 
of the skeletal radiographs performed over the years. This might be due to reduced 
osteoblast bound TNSALP activity and the associated hypomineralisation of bones.
To our knowledge, this is the first case report of a patient who has diagnosis of 
both Unverricht-Lundborg disease and hypophosphatasia. Although HPP did not have a 
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significant clinical impact for this patient, further studies would be required to elucidate if 
PLP might play a role in management of epilepsy associated with the rare Unverricht-
Lundborg syndrome.
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Table1. Bloods results on admission
Test (Units) Result Reference range
ALP  (U/L) 17 30-150 
Bilirubin (µmol/L) 9 <21
ALT (U/L) 103 <59
Albumin (g/L) 40 35-50




Phosphate (mmol/L 1.76 0.80-1.50
Vitamin D status 
(nmol/L) 
57 >50 (suggestive of 
adequate vitamin D 
status)
All analytes were measured using an automated Abbott Architect platform
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 Figure 1. Schematic representation of Serum concentration of ALP (U/L) over many years prior to initial 
presentation. 
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